Press Releases from Charles River
   
 
 
   
   

Charles River Announces First-Quarter 2008 Results 
 

Downloadable version.

  •  First-Quarter Sales Increase 16% to $338 Million Due to Strong Customer Demand
  • First-Quarter GAAP EPS of $0.64 and Non-GAAP EPS of $0.72
  • Reaffirms Guidance for 2008

 

WILMINGTON, Mass., May 06, 2008 (BUSINESS WIRE) -- Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the first quarter of 2008. For the quarter, net sales increased 16.0% to $337.7 million from $291.2 million in the first quarter of 2007. Both the Research Models and Services (RMS) and Preclinical Services (PCS) business segments reported strong sales growth, driven by demand for our broad portfolio of essential drug discovery and development products and services, as pharmaceutical and biotechnology companies invested in basic research and increased their strategic use of outsourced drug development services. Foreign exchange contributed 4.2% to the net sales growth.

Click here to read the full release.
   
Discover the full range of Charles River Products and Services
The Source

For more information, contact us at:

1.877.CRIVER.1 (1.877.274.8371)
askcharlesriver@crl.com

view all

News & Events

view all
Jan 23 - Introducing Eureka
Jan 20 - Access Preclinical Study Data with...
Feb 17-Feb 18 - Aichi, Japan - Japan Society of Experimental Diabetes and Obesity (JSED...
Feb 08-Feb 10 - Brussels, Belgium - 6th Charles River European Short Course on Laborato...
view all
Scientist I Wilmington, MA
Manager International Tax Wilmington, MA

Charles River Laboratories, Inc.